Ligand Pharma (LGND) Tops Q3 EPS by 116c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $316.13 --0%
Financial Fact:
Weighted average number of common shares - diluted: 23M
Today's EPS Names:
ROX, KEEL, SENEA, More
Financial Fact:
Weighted average number of common shares - diluted: 23M
Today's EPS Names:
ROX, KEEL, SENEA, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q3 EPS of $3.09, $1.16 better than the analyst estimate of $1.93. Revenue for the quarter came in at $115.46 million versus the consensus estimate of $57.22 million.
GUIDANCE:
Ligand Pharma sees FY2025 EPS of $7.40-$7.65, versus the consensus of $6.87. Ligand Pharma sees FY2025 revenue of $225-235 million, versus the consensus of $212.8 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ANI Pharma (ANIP) Tops Q3 EPS by 52c ; Offers Guidance
- Pyxis Oncology, Inc. (PYXS) Tops Q3 EPS by 4c
- Zenas BioPharma, Inc. (ZBIO) Reports Q3 Loss of $1.65
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
